Ester De Leo
Papers
1
Total Citations
42
H-Index
1
About
Ester De Leo is a trailblazer in the field of rare disease research, where she has pioneered the application of high-content drug screening to uncover therapies for conditions that are often overlooked by the pharmaceutical industry. Her most-cited work, "High‐content drug screening for rare diseases" (2017, 42 citations), addresses a critical gap: while individual rare diseases affect few patients, collectively they represent a massive unmet medical need. De Leo’s major contribution lies in adapting advanced phenotypic screening technologies to the unique constraints of rare disease biology—where patient samples are scarce and disease mechanisms are poorly understood. By demonstrating that high-content imaging and automated analysis can identify drug candidates from small-molecule libraries, she has provided a scalable, cost-effective pathway for repurposing existing drugs. Her work has not only catalyzed new therapeutic strategies but also empowered patient advocacy groups and academic consortia to pursue drug discovery independently. With a career dedicated to translating cellular biology into actionable treatments, De Leo stands as a key figure in democratizing rare disease therapy development, inspiring a generation of researchers to tackle the most neglected corners of medicine.
Research Focus
Key Achievements
Top Papers
- 1High‐content drug screening for rare diseases42 citations · 2017